Active substanceDextran [cf.m.m.mass 50,000-70000]Dextran [cf.m.m.mass 50,000-70000]
Similar drugsTo uncover
  • Polyglukin
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Polyglukin
    solution d / infusion 
  • Polyglukin
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Polyglukin
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Dosage form: & nbspsolution for infusions
    Composition:

    6% dextran solution (dextrose polymer) with a molecular weight of 50,000 to 70,000, obtained by a biosynthetic method using a microorganism Leuconostoc mesenteroides strain SF 4 and isotonic (0.9%) solution of sodium chloride.

    Description:

    Transparent, colorless or light yellow liquid.

    Pharmacotherapeutic group:plasma-substituting agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    Provides plazmozameschayuschee, antishock, replenishing the volume of circulating blood and antiaggregant effect. Due to the high osmotic pressure exceeding the oncotic pressure of plasma proteins by 2.5 times, it causes active involvement of tissue fluid (20-25 ml per 1 g of polymer) and keeps it in the vascular bed for a sufficiently long period, and therefore the volume of circulating blood in intravenous the introduction of the drug is quickly restored. Eliminates the disturbance of systemic hemodynamics, raises blood pressure.Increases the suspension resistance of blood, has a pronounced antiadhesive and antiaggregant effect on platelets, helps to eliminate peripheral stasis and erythrocyte aggregation, improves microcirculation, can reduce the risk of disseminated intravascular coagulation syndrome. Non-toxic, pyrogen-free.

    Pharmacokinetics:

    It is excreted mainly by the kidneys; during the first 24 hours, about 50% is eliminated, and after 3 days in the blood, only its traces are determined. A small part of dextran accumulates in the reticuloendothelial system, where it gradually undergoes metabolism to dextrose. From the bloodstream is completely removed for 5-7 days.

    Indications:

    Treatment of hemorrhagic, traumatic, burn, toxic and cardiogenic shock; preparation of patients for operation with the purpose of detoxification with burns and other conditions, accompanied by intoxication.

    Contraindications:

    Hypersensitivity to dextran, cardiovascular insufficiency, ongoing internal bleeding (liver, lungs, kidneys), traumatic brain injury, intracranial hypertension, hemorrhagic stroke, anuria,severe chronic renal failure, thrombocytopenia, clinical situations in which the introduction of large volumes of liquids (including arterial hypertension, hypervolemia against a hematocrit lower than 0.3) is undesirable.

    Carefully:Pronounced dehydration
    Pregnancy and lactation:

    At pregnancy a preparation appoint or nominate only on vital indications.

    Data on the contraindication of the drug during lactation there.

    Dosing and Administration:

    Intravenously struino or drip, with acute blood loss - intraarterially.

    The volume and speed of administration is determined by the patient's condition, blood pressure, heart rate, hematocrit.

    Transfusion is performed in the usual way in compliance with the rules of production of transfusion: before transfusion biological test (after the administration of 5-10 drops, a 3-minute break is made, then another 10-15 drops are added and after another break, in the absence of symptoms of the reaction (rapidity of the pulse, lowering of arterial pressure, skin hyperemia, difficulty breathing) continue to be transfused.

    With developed shock or acute blood loss - intravenously struino, 0.4-2 l (5-25 ml / kg). After increasing blood pressure to 80-90 mm Hg. usually pass to a drop introduction at a rate of 3-3.5 ml / min (60-80 cap / min). Possible intra-arterial route of administration (in the same dosages). Infusion of the drug should be carried out under constant control of the main indicators of systemic hemodynamics. With a significant increase in central venous pressure, reduce the dose and rate of administration or completely stop.

    With blood loss of more than 500-750 ml and severe anemia, the patient is combined with a blood transfusion, erythrocytic mass or red blood cell suspension necessary to eliminate tissue hypoxia, as well as fresh-frozen plasma containing hemostatic system factors.

    To prevent operational blood loss, as well as to achieve artificial hemodilution, prevent thrombosis and reduce the tendency to develop or progress the syndrome of disseminated intravascular coagulation the drug is administered in doses of 5-10 ml / kg (children - 10-15 ml / kg) for 30-60 minutes before surgery (in the case of a significant decrease in blood pressure go to the jet injection, with a drop in blood pressure below 60 mm Hg intraarterial administration.The volume of infusion during surgery is determined by the magnitude of operational blood loss (hematocrit should not fall below 0.3). In the postoperative period, drip-drop administration is an effective method of preventing shock.

    With burn shock: in the first 24 hours, 2-3 liters are introduced, in the next 24 hours, 1.5 liters. Children in the first 24 hours - 40-50 ml / kg, the next day - 30 ml / kg. With extensive and deep burns combined with the introduction of plasma, albumin, gamma globulin; with burns more than 30-40% of the body surface - with blood transfusion.

    To prevent possible dehydration of tissues it is recommended to combine the infusion of the drug with the introduction of crystalloid solutions in a ratio 1:2.

    Side effects:

    Allergic reactions (hyperemia and itching of the skin, angioedema).

    Overdose:

    With the rapid introduction of dextrans in large volumes, it is possible to provoke the development of acute left ventricular failure and pulmonary edema.

    In the case of complaints about a feeling of tightness in the chest, difficulty breathing, low back pain, as well as in case of chills, cyanosis, circulatory disturbance and breathing, transfusion should be stopped,intravenously, 10 ml of 10% calcium chloride solution, 20 ml of 40% dextrose solution, antihistamines, glucocorticosteroids and appropriate symptomatic therapy.

    Interaction:

    It can be combined with the introduction of other colloidal, water-salt and buffer solutions, as well as drugs used in complex therapy of shock.

    Aminocaproic acid, hydralazine, warfarin, ethanol 95%, dexamethasone and some other medicines are incompatible with dextrin.

    Special instructions:

    The drug can withstand freezing and can be transported at -10 ° C. Freezing of the preparation is not a contraindication to its use, provided the packaging is kept sealed.

    Patients with severe dehydration are required to restore fluid deficiency prior to administration of dextrans, the rate of their administration should not exceed 500 ml / h. The introduction of recommended doses practically does not affect the hemostasis system. Exceeding the recommended dose may prolong bleeding time. Against the background of dextrans induced hemodilution, a decrease in protein concentration in the blood plasma and hemoglobin is possible.The amount of dextrans to be administered should be calculated in such a way that it does not reduce the hemoglobin below 90 g / l (hematocrit 27%) for a longer or shorter time.

    The introduction of dextrans does not prevent the determination of the blood group and the conduct of a cross-sample by standard methods (it is recommended to wash the erythrocytes with 0.9% sodium chloride solution before the study).

    The presence of dextrin in the blood can influence the results of enzymatic methods based on papain.

    When studying the blood glucose content using solutions of sulfuric and acetic acids, you can get a glucose concentration greater than it actually is (the latter can hydrolyse the dextrin).

    Dextrin reduces the transparency of the blood, and its presence in the blood can change the results of measuring the concentration of bilirubin and protein. It is recommended to take blood samples to establish the concentration of bilirubin and protein before the injection of dextran.

    Form release / dosage:

    Solution for infusion, 6%.

    Packaging:

    In bottles of 100, 200, 400 ml.

    Bottle with instructions for use in an individual pack.

    For hospital: 48 bottles of 100 ml or 24 bottles of 200 ml or 12 bottles of 400 ml with 5-10 instructions for use in a box ofcorrugated cardboard.

    Bottles without bundles with an equal number of instructions for use are placed in a group package.

    Storage conditions:

    At temperatures from minus 10 to +25 ° C in a dry place inaccessible to children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N003493 / 01
    Date of registration:05.06.2009
    The owner of the registration certificate:KRASFARMA, JSC KRASFARMA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp10.01.2016
    Illustrated instructions
      Instructions
      Up